Spinal Cord Stimulation and Physical Therapy for Post-Stroke Upper-Limb Weakness
This study is investigating if combining the Medtronic Inceptiv™ System (a spinal cord stimulator) with physical therapy can help adults who have weakness in their arm and hand (hemiparesis) after a stroke. You might be able to join if you are between 22 and 70 years old and experienced an ischemic or hemorrhagic stroke more than 6 months ago that caused arm and hand weakness. The main goal is to see if the Medtronic system is safe for people who have had a stroke. Researchers also want to understand how spinal cord stimulation, when combined with physical therapy, affects motor control and helps reduce weakness. The study is currently unclear on its recruitment status, but plans to enroll 20 participants.
- Study design
- This is an interventional study planning to enroll 20 participants. It is divided into three phases, with participants first undergoing physical therapy alone, then physical therapy combined with spinal cord stimulation.
- What's involved
- You would participate in a Physical Training Protocol (PTP) for 6 weeks (3 sessions of 90 minutes each per week) before receiving the Medtronic implantable system. After the implant, you would repeat the same PTP program in combination with spinal cord stimulation during each rehabilitation session.
- Compensation
- Not stated in the trial record.
- Follow-up
- Your safety will be monitored from enrollment until the end of treatment at 49 weeks.
AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.
Spinal Cord Stimulation Combined With Physical Therapy in Post-Stroke Upper-Limb Motor Hemiparesis
At a glance
Conditions
NCT07153536
Where you'd take part
This study runs at 1 site. They're the same protocol — you choose where, and that choice sets who your contact draft is addressed to.
University of Pittsburgh
Pittsburgh, Pennsylvaniastudy coordinator listed
Recruiting
Sites open and close at different times, so the status above is per site — it can differ from the study's overall status.
Study leadership
- George Wittenberg, MD, PhD · PRINCIPAL_INVESTIGATOR · University of Pittsburgh
Who to contact
Opens a ready-to-send draft in your own email app — review before sending.
What this trial measures
- Number and Severity of Adverse EventsFrom enrollment to the end of treatment at 49 weeks
Success Criteria: no serious adverse events related to the stimulation or intolerable. adverse events reported